A randomized controlled trial was started in Japan to evaluate whether laparoscopic surgery is the optimal treatment for colorectal cancer. Patients with T3 or deeper carcinoma in the colorectum without transverse and descending colons are pre-operatively randomized to either open or laparoscopic colorectal resection. Surgeons in 24 specialized institutions will recruit 818 patients. The primary end-point is overall survival. Secondary end-points are relapse-free survival, short-term clinical outcome, adverse events, the proportion of conversion from laparoscopic surgery to open surgery, and the proportion of completion of laparoscopic surgery.
INTRODUCTION
The benefits of laparoscopic surgery (LAP) in comparison with open surgery (OPEN) have been suggested with respect to decreased morbidity, decreased pain, faster recovery and shorter hospital stay (1) (2) (3) (4) . However, the long-term survival of LAP for colorectal cancer is still unclear, especially for advanced colorectal cancer requiring extended lymphadenectomy. Thus, we designed a study which investigates whether LAP is suitable for advanced colorectal cancer with respect to survival and post-operative morbidity 
END-POINTS
The primary end-point is overall survival. Secondary endpoints are relapse-free survival, short-term clinical outcomes, adverse events, the proportion of conversion from LAP to OPEN and the proportion of completion of LAP. All LAP cases which require skin incision >8 cm are counted as a conversion to OPEN, except for those in which retrieval of the resected specimen alone requires this length of incision. The completion of LAP is defined as completion of the curative operation without conversion to OPEN. The short-term clinical outcomes are proportion of use of analgesics, duration from operation to flatus, highest body temperature during hospitalization and highest body temperature during the 3 days after the operation.
ELIGIBILITY CRITERIA
Tumors are staged according to the TNM classification system.
Inclusion criteria. For inclusion in the study, patients must fulfill the following requirements pre-operatively: (i) histologically proven colorectal carcinoma; (ii) tumor located in the cecum, ascending colon, sigmoid colon or rectosigmoid colon; (iii) T3 or deeper lesion without involvement of other organs; (iv) without multiple lesions other than carcinoma in situ; (v) cancer classified as N0-2 and M0, according to the TNM classification system; (vi) tumor size <8 cm; (vii) no bowel obstruction; (viii) age >20 and <75 years; (ix) sufficient organ function; (x) no history of gastrointestinal surgery; (xi) no history of chemotherapy or radiotherapy; and (xii) provide written informed consent.
Exclusion criteria. Exclusion criteria are as follows: (i) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ; (ii) severe pulmonary emphysema, interstitial pneumonitis or ischemic heart disease; (iii) pregnant or lactating women; (iv) severe mental disease; and (v) continuous systemic steroid therapy.
RANDOMIZATION
By telephone or fax to the JCOG Data Center after confirmation of the inclusion/exclusion criteria, the patients are randomized by the minimization method of balancing the arm according to the location of tumor and institution.
QUALITY CONTROL OF SURGERY
To control the quality of the operation, we limit the operator to accredited surgeons and perform central review of the surgical procedure by photograph in all patients and by videotape in arbitrarily selected patients in both the LAP and OPEN arms. 
FOLLOW-UP
Patients are observed by their surgeon every 4 months for the first 2 years and then every 6 months for 3 years after operation. Blood tests, abdominal computed tomography and plain chest X-ray are carried out at each visit.
STUDY DESIGN AND STATISTICAL METHOD
This trial is designed to evaluate the non-inferiority of LAP to standard OPEN in terms of overall survival. If the overall survival is equivalent, LAP will be the preferred treatment.
The null hypothesis to be tested is that the hazard ratio for the primary end-point with the LAP technique, as compared with the OPEN technique, was 1.366. The planned sample size is 818, 409 cases per arm, with 5 years of follow-up after 3 years of accrual. This provides 80% power to reject the null hypothesis when the survival is equivalent. This calculation assumed that there was a 5-year survival of 75% among patients treated with the OPEN technique.
INTERIM ANALYSIS AND MONITORING
Interim analysis is planned to take place twice, taking multiplicity into account by the Lan-Demets method with O'Brien and Fleming type boundaries. The Data and Safety Monitoring Committee (DSMC) of the JCOG will independently review the interim analysis report and consider stopping the trial early. In-house interim monitoring will be performed by the Data Center to ensure data submission and study progress. The monitoring reports will be submitted to and reviewed by the CCSG every 6 months. 
